Check for updates

OPEN ACCESS

EDITED BY Yaozu Xiang, Tongji University, China

REVIEWED BY Zehuai Wen, Guangzhou University of Chinese Medicine, China Jing Hu, Beijing TCM hospital, China

*CORRESPONDENCE Jingbo Zhai Image: zhaijingbo@foxmail.com Yunhui Hu Image: tsl-huyunhui@tasly.com

RECEIVED 21 February 2023 ACCEPTED 24 April 2023 PUBLISHED 22 May 2023

CITATION

Zhang M, Wang W, Sun H, Zhai J and Hu Y (2023) Compound danshen dripping pills vs. nitrates for stable angina pectoris: a systematic review and meta-analysis. Front. Cardiovasc. Med. 10:1168730. doi: 10.3389/fcvm.2023.1168730

COPYRIGHT

© 2023 Zhang, Wang, Sun, Zhai and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Compound danshen dripping pills vs. nitrates for stable angina pectoris: a systematic review and meta-analysis

Mengying Zhang¹, Wenjia Wang¹, He Sun^{1,2}, Jingbo Zhai^{3*} and Yunhui Hu^{1*}

¹Tasly Pharmaceutical Group Co., Ltd., Tianjin, China, ²The State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tasly Academy, Tasly Holding Group Co., Ltd., Tianjin, China, ³School of Public Health, Tianjin University of Traditional Chinese Medicine, Tianjin, China

Background: Long-term use of nitrates for treating stable angina pectoris (SAP) may lead to patients' tolerance to nitrates. As a traditional Chinese medicine, Compound danshen dropping pills (CDDP) is beneficial for patients with SAP. This study aimed to critically assess the efficacy and safety of CDDP vs. nitrates for SAP.

Methods: PubMed, Embase, Web of Science, Cochrane library, CNKI, Wanfang Digital Periodicals, and Chinese Science and Technology Periodicals database were searched from inception to April 2023. Randomized controlled trials (RCTs) comparing CDDP with nitrates for SAP were included. The meta-analysis was conducted to estimate the pooled effect.

Results: Twenty-nine studies were included for the statistical analysis. The metaanalyses with the random-effect model indicated that CDDP could significantly increase the effective rate in symptom improvement compared with nitrates (Pooled 9 RCTs, OR = 1.95, 95% CI: 1.25-3.05, P = 0.003, duration of 4 weeks; Pooled 4 RCTs, OR = 3.45, 95% CI: 1.84-6.48, P = 0.0001, duration of 6 weeks; Pooled 13 RCTs, OR = 4.02, 95% CI: 2.14-7.57, P < 0.0001, duration of 8 weeks). The meta-analyses with the random-effect model indicated that CDDP could significantly increase the effective rate in electrocardiogram improvement compared with nitrates (Pooled 5 RCTs, OR = 1.60, 95% CI: 1.02-2.52, P = 0.04, duration of 4 weeks; Pooled 3 RCTs, OR = 2.47, 95% CI: 1.60-3.82, P<0.0001, duration of 6 weeks; Pooled 11 RCTs, OR = 3.43, 95% CI: 2.68–4.38, P<0.00001, duration of 8 weeks). The incidence of adverse drug reactions in the CDDP group was lower than that in the nitrates group (Pooled 23 RCTs, OR = 0.15, 95% CI: 0.1-0.21, P < 0.00001). The results of the metaanalyses with fixed-effect model were similar with above results. The levels of the evidence ranged from very low to low.

Conclusion: The present study suggests that CDDP with the duration of at least 4 weeks can be considered as an alternative to nitrates for treating SAP. However, more high-quality RCTs are still needed to confirm these findings.

Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record. php?ID=CRD42022352888, identifier [CRD42022352888].

KEYWORDS

compound danshen dripping pills (CDDP), nitrates, stable angina pectoris (SAP), systematic review, meta-analysis

1. Introduction

Stable angina pectoris (SAP) is one of the most common manifestations of coronary artery disease (CAD) (1). A survey reported that the prevalence of chronic SAP was 7.7% in Iran (2). A prospective study showed that 20% of patients with CAD had symptoms related with angina pectoris, which may be associated with an increased risk of adverse cardiovascular outcomes (3). A cohort study found that the high frequency of angina pectoris was associated with the high incidence of secondary cardiovascular events and death in patients with stable coronary heart disease (4).

At present, the goals of treatments for SAP mainly focus on the reduction in cardiovascular adverse events and the improvement in the quality of life (5). There are many antianginal therapies, such as nitrates, beta-blockers, calcium channel blockers and ranolazine (5). Nitrates as standard antianginal treatments have been used in the management of angina pectoris for many years (6). A systematic review found that nitrates could significantly reduce the angina attacks and improve the exercise duration (6). However, some adverse events associated with nitrates are reported, such as headache and dizziness (6). Moreover, long-term use may lead to patients' tolerance to nitrates and the reduction of protection duration (7).

Traditional Chinese medicine (TCM) is beneficial for the management of angina pectoris. A systematic review showed that TCM could reduce the frequency of angina pectoris, shorten the duration of angina attack and improve the quality of life (8). Compound danshen dropping pills (CDDP) is a TCM formula, and is composed of Salvia miltiorrhiza Bunge, Panax notoginseng (Burkill) F.H. Chen and Dryobalanops aromatica C.F. Gaertn. TCM network pharmacology is a new approach to understanding herb formula (9, 10). A study based on the network pharmacology and molecular docking found that the mechanisms of CDDP for treating SAP might be associated with the regulation of inflammatory response, apoptosis signal pathway, etc. (11). Some clinical trials comparing CDDP with nitrates for SAP have been published in recent years. However, the relative advantages and disadvantages of CDDP compared with nitrates for SAP were not systematically evaluated. Therefore, we conducted this systematic review to critically assess the efficacy and safety of CDDP vs. nitrates for SAP.

2. Methods

This study was registered on PROSPERO (No. CRD42022352888) available from: https://www.crd.york.ac.uk/prospero/display_record. php?ID=CRD42022352888. It followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement (12).

2.1. Inclusion and exclusion criteria

2.1.1. Type of included studies

Randomized controlled trials (RCTs) were considered for inclusion, regardless of publication date and language.

Quasi-RCTs, cross-over trials, on-going trials, abstracts and letters were excluded.

2.1.2. Patients

Patients diagnosed with SAP were included. Age, gender, race and nationality were unrestricted. SAP should be assessed according to the internationally recognized criteria or guidelines, such as National Institute for Health and Care Excellence or European Society of Cardiology guidelines (13).

2.1.3. Interventions

CDDP was used to treat SAP in the experimental group. Nitrates were used for the management of SAP in the control group. According to the instruction of CDDP, patients should take CDDP ten pills a time, and three times a day for at least 4 weeks. The dosage, frequency and course of nitrates were unlimited. The types of nitrates such as isosorbide dinitrate and isosorbide nitrate were also unrestricted. Other specific interventions for treating SAP were inhibited in the two groups. Patients with SAP may be accompanied with other diseases, such as coronary heart disease. Conventional therapies for the management of these accompanied diseases were unlimited.




TABLE 1 Characteristics of included studies.

Author and Publication year	Sample size (E)	Sample size (C)	Intervention (E)	Intervention (C)	Dosage of CDDP	Duration of CDDP	Dosage of ID or IN	Duration of ID or IN	Outcomes
Liu 1997	62	30	CDDP	ID	810 mg/day	6 weeks	30 mg/day	6 weeks	AR
Zhou 1998	120	60	CDDP	IN	810 mg/day	2 months	30 mg/day	2 months	ERSI,MERSI, EREI, MEREI, AR
Ding 1999	52	50	CDDP	ID	810 mg/day	2 months	30 mg/day	2 months	ERSI,MERSI, AR
Zhang 1999	69	64	CDDP	ID	810 mg/day	30 days	30 mg/day	30 days	ERSI,MERSI, AR
Gao 2000	60	60	CDDP	ID	810 mg/day	8 weeks	30 mg/day	8 weeks	ERSI,MERSI, EREI, MEREI, AR
Tan 2001	40	40	CDDP	ID	810 mg/day	4 weeks	30 mg/day	4 weeks	ERSI,MERSI, EREI, MEREI
Lu 2001	60	60	CDDP	ID	810 mg/day	8 weeks	30 mg/day	8 weeks	ERSI,MERSI, EREI, MEREI
Zhu 2001	80	80	CDDP	ID	810 mg/day	8 weeks	30 mg/day	8 weeks	ERSI,MERSI, EREI, MEREI
Yang 2001	43	40	CDDP	ID	810 mg/day	8 weeks	30 mg/day	8 weeks	ERSI,MERSI, EREI, MEREI, AR
Shi 2001	102	51	CDDP	ID	810 mg/day	4 weeks	30 mg/day	4 weeks	ERSI,MERSI, AR
Dong 2001	30	30	CDDP	ID	810 mg/day	4 weeks	30 mg/day	4 weeks	ERSI,MERSI, EREI, MEREI, AR
Xue 2001	102	90	CDDP	ID	810 mg/day	45 days	30 mg/day	45 days	ERSI,MERSI, EREI, MEREI, AR
Guo 2001	25	25	CDDP	ID	810 mg/day	8 weeks	30 mg/day	8 weeks	ERSI,MERSI, EREI, MEREI
Deng 2002	56	30	CDDP	ID	810 mg/day	8 weeks	30 mg/day	8 weeks	ERSI,MERSI, AR
Yao 2002a	50	50	CDDP	ID	810 mg/day	8 weeks	30 mg/day	8 weeks	ERSI,MERSI, EREI, MEREI
Yao 2002b	50	50	CDDP	ID	810 mg/day	4 weeks	30 mg/day	4 weeks	AR
Wang 2003	52	50	CDDP	ID	810 mg/day	2 months	30 mg/day	2 months	ERSI,MERSI, EREI, MEREI, AR
Chu 2003	35	32	CDDP	ID	810 mg/day	60 days	30 mg/day	60 days	ERSI,MERSI, EREI, MEREI
Huang 2004	40	38	CDDP	ID	810 mg/day	2 months	30 mg/day	2 months	AR
Li 2005	70	60	CDDP	IN	810 mg/day	6 weeks	30 mg/day	6 weeks	EREI,MEREI, AR
Li 2006	56	50	CDDP	IN	810 mg/day	6 weeks	30 mg/day	6 weeks	ERSI,MERSI, AR
Chi 2007	120	114	CDDP	ID	810 mg/day	4 weeks	30 mg/day	4 weeks	ERSI,MERSI, EREI, MEREI, AR
Yue 2008	55	53	CDDP	IN	810 mg/day	1 month	30 mg/day	1 month	ERSI,MERSI, AR
Pan 2008	50	30	CDDP	ID	810 mg/day	6 weeks	30 mg/day	6 weeks	ERSI,MERSI, AR
Luo 2008	54	52	CDDP	IN	810 mg/day	1 month	30 mg/day	1 month	ERSI,MERSI, AR
Wang 2009	29	28	CDDP	ID	810 mg/day	6 weeks	30 mg/day	6 weeks	AR
Zhang 2009	30	30	CDDP	ID	810 mg/day	8 weeks	30 mg/day	8 weeks	ERSI,MERSI, EREI, MEREI, AR
Gong 2013	60	60	CDDP	IN	810 mg/day	12 weeks	30 mg/day	12 weeks	AR
Shao 2013	66	60	CDDP	IN	810 mg/day	1 month	30 mg/day	1 month	AR


E, Experimental group; C, Control group; CDDP, compound danshen dripping pills; ID, isosorbide dinitrate; IN, isosorbide nitrate; ERSI, Effective rate in symptom improvement; MERSI, Markedly effective rate in symptom improvement; EREI, Effective rate in ECG improvement; MEREI, Markedly effective rate in ECG improvement; AR, Adverse reaction.

2.1.4. Outcomes

The primary outcomes were the effective rate and markedly effective rate in symptom improvement (14). The secondary outcomes included the effective rate and markedly effective rate in electrocardiogram (ECG) improvement, and adverse drug reactions. The patients were labeled as "effective" in symptom improvement when the frequency of angina attacks and nitroglycerin consumption were reduced by more than 50%, and "markedly effective" in symptom improvement when symptoms associated with SAP were disappeared, the frequency of angina attacks or nitroglycerin consumption was reduced by more than 80% or 90% after treatment. The patients were labeled as "effective" in ECG improvement when S-T segment was elevated by 0.5 mm, however, not recovered completely after treatment, or defined by guidelines. The patients were labeled as "markedly effective" in ECG improvement when resting electrocardiogram returned to normal level after treatment, or defined by guidelines. The effective rate is equal to the number of patients labeled as "effective" or "markedly effective" divided by the total number of patients in one group. The markedly effective rate is equal to the number of patients labeled as "markedly effective" divided by the total number of patients in one group.

2.2. Search strategy

Two reviewers (JZ and MZ) independently searched PubMed, Embase, Web of Science, Cochrane library, China National Knowledge Infrastructure, Wanfang Digital Periodicals, and Chinese Science and Technology Periodicals database from inception to April 2023. The search terms included ("compound danshen dripping pills" OR "fufang danshen diwan" OR "Cardiotonic Pills" OR "dantonic" OR T89) AND (nitrate OR "isosorbide dinitrate" OR "isosorbide nitrate") AND ("stable angina" OR "angina" OR "angina pectoris" OR "stenocardia" OR "angor pectoris"). Moreover, ClinicalTrials.gov, World Health Organization International Clinical trials Registry platform, and Chinese Clinical Trial Registry were also be searched to identify potentially grey literatures. The detailed search strategies are attainable in **Supplementary Material**.



2.3. Study selection

The studies collected from the comprehensive literature search were imported into EndNote X9 software to remove duplicates. Then, two reviewers (JZ and MZ) independently checked titles and abstracts to delete obviously ineligible studies according to the inclusion and exclusion criteria. They checked the full texts of the remaining studies to further identify eligible studies.



Disagreements were handled in consultation with a third reviewer (YH). A PRISMA flow diagram was used to describe the screening process.

2.4. Data extraction

The important data were extracted and imported into Microsoft Excel 2013 by two authors (JZ and MZ) independently. The information included characteristic of included studies (first author, publication year, country, sample size, design), patients (age, gender, race, nationality), interventions (type, dosage, frequency, duration), and outcomes (primary and secondary outcomes). The information on risk of bias assessment (randomization, allocation, blinding, loss to follow-up) were also extracted synchronously.

2.5. Assessment of risk of bias


The risk of bias for included RCTs was assessed by the Cochrane "risk of bias" tool. The selection bias, performance bias, detection bias, attrition bias, and reporting bias for each included RCT was classified to low, high or unclear level. Two reviewers (JZ and MZ) were independently assessed the risk of bias. Any disagreement was resolved by a third author (YH).

	CDD		Nitrat		Maint	Odds Ratio	Odds Ratio
Study or Subgroup	Events	lotal	Events	lotal	weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
About 4 weeks							
Chi 2007	106	120	104	114	18.2%	0.73 [0.31, 1.71]	
Dong 2001	26	30	18	30	9.9%	4.33 [1.20, 15.61]	
Guo 2001	22	25	18	25	7.7%	2.85 [0.64, 12.64]	
Luo 2008	51	54	47	52	7.7%	1.81 [0.41, 7.99]	
Shi 2001	96	102	45	51	11.2%	2.13 [0.65, 6.98]	
Tan 2001	37	40	30	40	8.8%	4.11 [1.04, 16.29]	
Xue 2001	92	102	68	90	19.5%	2.98 [1.32, 6.69]	
Yue 2008	50	55	48	53	9.7%	1.04 [0.28, 3.83]	
Zhang 1999	66	69	60	64	7.3%	1.47 [0.32, 6.82]	
Subtotal (95% CI)		597		519	100.0%	1.95 [1.25, 3.05]	•
Total events	546		438				
Heterogeneity: Tau ² =	= 0.09; Chi	² = 10.	06, df = 8	(P = 0.	26); I ^z = 2	0%	
Test for overall effect	: Z = 2.94 (P = 0.0	03)				
About 6 weeks							
Guo 2001	22	25	17	25	17.0%	3.45 [0.79, 15.01]	
Li 2006	52	56	45	50	19.3%	1.44 [0.37, 5.71]	
Pan 2008	48	50	21	30	14.3%	10.29 [2.04, 51.75]	
Xue 2001	92	102	65	90	49.4%	3.54 [1.59, 7.87]	
Subtotal (95% CI)		233		195	100.0%	3.45 [1.84, 6.48]	-
Total events	214		148				
Heterogeneity: Tau ² =	= 0.04; Chi	² = 3.3	1,df=3 (P = 0.3	5); I² = 99	6	
Test for overall effect	: Z = 3.86 ((P = 0.0	0001)				
About 0 weeks							
About 8 weeks							
Chu 2003	32	35	29	32	6.6%	1.10 [0.21, 5.90]	
Chu 2003 Deng 2002	54	56	21	30	6.8%	11.57 [2.31, 58.06]	
Chu 2003 Deng 2002 Ding 1999	54 48	56 52	21 45	30 50	6.8% 7.8%	11.57 [2.31, 58.06] 1.33 [0.34, 5.28]	
Chu 2003 Deng 2002 Ding 1999 Gao 2000	54 48 55	56 52 60	21 45 21	30 50 60	6.8% 7.8% 9.1%	11.57 [2.31, 58.06] 1.33 [0.34, 5.28] 20.43 [7.09, 58.85]	
Chu 2003 Deng 2002 Ding 1999 Gao 2000 Guo 2001	54 48 55 24	56 52 60 25	21 45 21 16	30 50 60 25	6.8% 7.8% 9.1% 5.0%	11.57 [2.31, 58.06] 1.33 [0.34, 5.28] 20.43 [7.09, 58.85] 13.50 [1.56, 117.14]	
Chu 2003 Deng 2002 Ding 1999 Gao 2000 Guo 2001 Lu 2001	54 48 55 24 56	56 52 60 25 60	21 45 21 16 55	30 50 60 25 60	6.8% 7.8% 9.1% 5.0% 7.8%	11.57 [2.31, 58.06] 1.33 [0.34, 5.28] 20.43 [7.09, 58.85] 13.50 [1.56, 117.14] 1.27 [0.32, 4.99]	
Chu 2003 Deng 2002 Ding 1999 Gao 2000 Guo 2001 Lu 2001 Wang 2003	54 48 55 24 56 48	56 52 60 25 60 52	21 45 21 16 55 46	30 50 60 25 60 50	6.8% 7.8% 9.1% 5.0% 7.8% 7.5%	11.57 [2.31, 58.06] 1.33 [0.34, 5.28] 20.43 [7.09, 58.85] 13.50 [1.56, 117.14] 1.27 [0.32, 4.99] 1.04 [0.25, 4.42]	
Chu 2003 Deng 2002 Ding 1999 Gao 2000 Guo 2001 Lu 2001 Wang 2003 Xue 2001	54 48 55 24 56 48 97	56 52 60 25 60 52 102	21 45 21 16 55 46 60	30 50 60 25 60 50 90	6.8% 7.8% 9.1% 5.0% 7.8% 7.5% 9.4%	11.57 [2.31, 58.06] 1.33 [0.34, 5.28] 20.43 [7.09, 58.85] 13.50 [1.56, 117.14] 1.27 [0.32, 4.99] 1.04 [0.25, 4.42] 9.70 [3.57, 26.37]	
Chu 2003 Deng 2002 Ding 1999 Gao 2000 Guo 2001 Lu 2001 Wang 2003 Xue 2001 Yang 2001	54 48 55 24 56 48 97 40	56 52 60 25 60 52 102 43	21 45 21 16 55 46 60 25	30 50 60 25 60 50 90 40	6.8% 7.8% 9.1% 5.0% 7.8% 7.5% 9.4% 7.9%	11.57 [2.31, 58.06] 1.33 [0.34, 5.28] 20.43 [7.09, 58.85] 13.50 [1.56, 117.14] 1.27 [0.32, 4.99] 1.04 [0.25, 4.42] 9.70 [3.57, 26.37] 8.00 [2.10, 30.45]	
Chu 2003 Deng 2002 Ding 1999 Gao 2000 Guo 2001 Lu 2001 Wang 2003 Xue 2001 Yang 2001 Yang 2002 a	54 48 55 24 56 48 97 40 48	56 52 60 25 60 52 102 43 50	21 45 21 16 55 46 60 25 33	30 50 60 25 60 50 90 40 50	6.8% 7.8% 9.1% 5.0% 7.8% 7.5% 9.4% 7.9% 7.1%	11.57 [2.31, 58.06] 1.33 [0.34, 5.28] 20.43 [7.09, 58.85] 13.50 [1.56, 117.14] 1.27 [0.32, 4.99] 1.04 [0.25, 4.42] 9.70 [3.57, 26.37] 8.00 [2.10, 30.45] 12.36 [2.68, 57.14]	
Chu 2003 Deng 2002 Ding 1999 Gao 2000 Guo 2001 Lu 2001 Wang 2003 Xue 2001 Yang 2001 Yang 2001 Yao 2002 a Zhang 2009	54 48 55 24 56 48 97 40	56 52 60 25 60 52 102 43 50 30	21 45 21 16 55 46 60 25 33 22	30 50 60 25 60 50 90 40 50 30	6.8% 7.8% 9.1% 5.0% 7.8% 7.5% 9.4% 7.9% 7.1% 6.7%	11.57 [2.31, 58.06] 1.33 [0.34, 5.28] 20.43 [7.09, 58.85] 13.50 [1.56, 117.14] 1.27 [0.32, 4.99] 1.04 [0.25, 4.42] 9.70 [3.57, 26.37] 8.00 [2.10, 30.45]	
Chu 2003 Deng 2002 Ding 1999 Gao 2000 Guo 2001 Lu 2001 Wang 2003 Xue 2001 Yang 2001 Yang 2001 Yao 2002 a Zhang 2009 Zhou 1998	54 48 55 24 56 48 97 40 48 28 28 112	56 52 60 25 60 52 102 43 50 30 120	21 45 21 16 55 46 60 25 33 22 52	30 50 60 25 60 50 90 40 50 30 60	6.8% 7.8% 9.1% 5.0% 7.8% 7.5% 9.4% 7.9% 7.1%	11.57 [2.31, 58.06] 1.33 [0.34, 5.28] 20.43 [7.09, 58.85] 13.50 [1.56, 117.14] 1.27 [0.32, 4.99] 1.04 [0.25, 4.42] 9.70 [3.57, 26.37] 8.00 [2.10, 30.45] 12.36 [2.68, 57.14] 5.09 [0.98, 26.43] 2.15 [0.77, 6.06]	
Chu 2003 Deng 2002 Ding 1999 Gao 2000 Guo 2001 Lu 2001 Wang 2003 Xue 2001 Yang 2001 Yang 2001 Yao 2002 a Zhang 2009 Zhou 1998 Zhu 2001	54 48 55 24 56 48 97 40 48 28	56 52 60 25 60 52 102 43 50 30 120 80	21 45 21 16 55 46 60 25 33 22	30 50 60 25 60 50 90 40 50 30 60 80	6.8% 7.8% 9.1% 5.0% 7.8% 7.5% 9.4% 7.9% 7.1% 6.7% 9.2% 8.9%	11.57 [2.31, 58.06] 1.33 [0.34, 5.28] 20.43 [7.09, 58.85] 13.50 [1.56, 117.14] 1.27 [0.32, 4.99] 1.04 [0.25, 4.42] 9.70 [3.57, 26.37] 8.00 [2.10, 30.45] 12.36 [2.68, 57.14] 5.09 [0.98, 26.43] 2.15 [0.77, 6.06] 1.37 [0.45, 4.15]	
Chu 2003 Deng 2002 Ding 1999 Gao 2000 Guo 2001 Lu 2001 Wang 2003 Xue 2001 Yang 2001 Yang 2001 Yao 2002 a Zhang 2009 Zhou 1998 Zhu 2001 Subtotal (95% CI)	54 48 55 24 56 48 97 40 48 28 112 74	56 52 60 25 60 52 102 43 50 30 120	21 45 21 16 55 46 60 25 33 22 52 72	30 50 60 25 60 50 90 40 50 30 60 80	6.8% 7.8% 9.1% 5.0% 7.8% 7.5% 9.4% 7.9% 7.1% 6.7% 9.2%	11.57 [2.31, 58.06] 1.33 [0.34, 5.28] 20.43 [7.09, 58.85] 13.50 [1.56, 117.14] 1.27 [0.32, 4.99] 1.04 [0.25, 4.42] 9.70 [3.57, 26.37] 8.00 [2.10, 30.45] 12.36 [2.68, 57.14] 5.09 [0.98, 26.43] 2.15 [0.77, 6.06]	
Chu 2003 Deng 2002 Ding 1999 Gao 2000 Guo 2001 Lu 2001 Wang 2003 Xue 2001 Yang 2001 Yang 2001 Yao 2002 a Zhang 2009 Zhou 1998 Zhu 2001 Subtotal (95% CI) Total events	54 48 55 24 56 48 97 40 48 28 112 74 74	56 52 60 25 60 52 102 43 50 30 120 80 765	21 45 21 16 55 46 60 25 33 22 52 72 497	30 50 60 50 90 40 50 30 60 80 657	6.8% 7.8% 9.1% 5.0% 7.5% 9.4% 7.9% 7.1% 6.7% 9.2% 8.9% 100.0%	11.57 [2.31, 58.06] 1.33 [0.34, 5.28] 20.43 [7.09, 58.85] 13.50 [1.56, 117.14] 1.27 [0.32, 4.99] 1.04 [0.25, 4.42] 9.70 [3.57, 26.37] 8.00 [2.10, 30.45] 12.36 [2.68, 57.14] 5.09 [0.98, 26.43] 2.15 [0.77, 6.06] 1.37 [0.45, 4.15] 4.02 [2.14, 7.57]	
Chu 2003 Deng 2002 Ding 1999 Gao 2000 Guo 2001 Lu 2001 Wang 2003 Xue 2001 Yang 2001 Yang 2001 Yao 2002 a Zhang 2009 Zhou 1998 Zhu 2001 Subtotal (95% CI)	54 48 55 24 56 48 97 40 48 28 112 74 74	56 52 60 25 60 52 102 43 50 30 120 80 765	21 45 21 16 55 46 60 25 33 22 52 72 497	30 50 60 50 90 40 50 30 60 80 657	6.8% 7.8% 9.1% 5.0% 7.5% 9.4% 7.9% 7.1% 6.7% 9.2% 8.9% 100.0%	11.57 [2.31, 58.06] 1.33 [0.34, 5.28] 20.43 [7.09, 58.85] 13.50 [1.56, 117.14] 1.27 [0.32, 4.99] 1.04 [0.25, 4.42] 9.70 [3.57, 26.37] 8.00 [2.10, 30.45] 12.36 [2.68, 57.14] 5.09 [0.98, 26.43] 2.15 [0.77, 6.06] 1.37 [0.45, 4.15] 4.02 [2.14, 7.57]	
Chu 2003 Deng 2002 Ding 1999 Gao 2000 Guo 2001 Lu 2001 Wang 2003 Xue 2001 Yang 2001 Yang 2001 Yao 2002 a Zhang 2009 Zhou 1998 Zhu 2001 Subtotal (95% CI) Total events	54 48 55 24 56 48 97 40 48 28 112 74 74 716 = 0.85; Chi	56 52 60 52 102 43 50 30 120 80 765 ² = 34.2	21 45 21 16 55 46 60 25 33 22 22 72 72 497 22, df = 1	30 50 60 50 90 40 50 30 60 80 657	6.8% 7.8% 9.1% 5.0% 7.5% 9.4% 7.9% 7.1% 6.7% 9.2% 8.9% 100.0%	11.57 [2.31, 58.06] 1.33 [0.34, 5.28] 20.43 [7.09, 58.85] 13.50 [1.56, 117.14] 1.27 [0.32, 4.99] 1.04 [0.25, 4.42] 9.70 [3.57, 26.37] 8.00 [2.10, 30.45] 12.36 [2.68, 57.14] 5.09 [0.98, 26.43] 2.15 [0.77, 6.06] 1.37 [0.45, 4.15] 4.02 [2.14, 7.57]	
Chu 2003 Deng 2002 Ding 1999 Gao 2000 Guo 2001 Lu 2001 Wang 2003 Xue 2001 Yao 2002 a Zhang 2009 Zhou 1998 Zhou 1998 Zhu 2001 Subtotal (95% CI) Total events Heterogeneity: Tau ² =	54 48 55 24 56 48 97 40 48 28 112 74 74 716 = 0.85; Chi	56 52 60 52 102 43 50 30 120 80 765 ² = 34.2	21 45 21 16 55 46 60 25 33 22 22 72 72 497 22, df = 1	30 50 60 50 90 40 50 30 60 80 657	6.8% 7.8% 9.1% 5.0% 7.8% 7.5% 9.4% 7.9% 7.1% 6.7% 9.2% 8.9% 100.0%	11.57 [2.31, 58.06] 1.33 [0.34, 5.28] 20.43 [7.09, 58.85] 13.50 [1.56, 117.14] 1.27 [0.32, 4.99] 1.04 [0.25, 4.42] 9.70 [3.57, 26.37] 8.00 [2.10, 30.45] 12.36 [2.68, 57.14] 5.09 [0.98, 26.43] 2.15 [0.77, 6.06] 1.37 [0.45, 4.15] 4.02 [2.14, 7.57]	
Chu 2003 Deng 2002 Ding 1999 Gao 2000 Guo 2001 Lu 2001 Wang 2003 Xue 2001 Yao 2002 a Zhang 2009 Zhou 1998 Zhou 1998 Zhu 2001 Subtotal (95% CI) Total events Heterogeneity: Tau ² =	54 48 55 24 56 48 97 40 48 28 112 74 74 716 = 0.85; Chi	56 52 60 52 102 43 50 30 120 80 765 ² = 34.2	21 45 21 16 55 46 60 25 33 22 22 72 72 497 22, df = 1	30 50 60 50 90 40 50 30 60 80 657	6.8% 7.8% 9.1% 5.0% 7.8% 7.5% 9.4% 7.9% 7.1% 6.7% 9.2% 8.9% 100.0%	11.57 [2.31, 58.06] 1.33 [0.34, 5.28] 20.43 [7.09, 58.85] 13.50 [1.56, 117.14] 1.27 [0.32, 4.99] 1.04 [0.25, 4.42] 9.70 [3.57, 26.37] 8.00 [2.10, 30.45] 12.36 [2.68, 57.14] 5.09 [0.98, 26.43] 2.15 [0.77, 6.06] 1.37 [0.45, 4.15] 4.02 [2.14, 7.57]	
Chu 2003 Deng 2002 Ding 1999 Gao 2000 Guo 2001 Lu 2001 Wang 2003 Xue 2001 Yao 2002 a Zhang 2009 Zhou 1998 Zhou 1998 Zhu 2001 Subtotal (95% CI) Total events Heterogeneity: Tau ² =	54 48 55 24 56 48 97 40 48 28 112 74 716 = 0.85; Chi : Z = 4.31 (56 52 60 25 60 52 102 43 50 30 120 80 765 765 7 ≤ 34.2 P ≤ 0.0	21 45 21 16 55 46 60 25 33 22 52 72 497 22, df = 1 0001)	30 50 60 25 60 90 40 50 30 60 80 657 2 (P = 0	6.8% 7.8% 9.1% 5.0% 7.8% 7.5% 9.4% 7.9% 6.7% 9.2% 8.9% 100.0%	11.57 [2.31, 58.06] 1.33 [0.34, 5.28] 20.43 [7.09, 58.85] 13.50 [1.56, 117.14] 1.27 [0.32, 4.99] 1.04 [0.25, 4.42] 9.70 [3.57, 26.37] 8.00 [2.10, 30.45] 12.36 [2.68, 57.14] 5.09 [0.98, 26.43] 2.15 [0.77, 6.06] 1.37 [0.45, 4.15] 4.02 [2.14, 7.57] *= 65%	0.01 0.1 0.1 10 100

Meta-analyses on effective rate in symptom improvement.

TABLE 2 Meta-analyses with fixed-effect model.

Outcomes	Duration of CDDP	Number of included	OR	95% Cl		P value
	treatment	studies		Lower limit	Upper limit	
Effective rate in symptom improvement	4 weeks	8	1.95	1.32	2.87	0.0007
	6 weeks	4	3.52	1.99	6.24	< 0.0001
	8 weeks	13	4.57	3.26	6.4	< 0.00001
Markedly effective rate in symptom	4 weeks (standard 1)	3	1.26	0.75	2.1	0.38
improvement	4 weeks (standard 2)	6	1.54	1.15	2.05	0.003
	6 weeks (standard 1)	2	1.56	0.86	2.81	0.14
	6 weeks (standard 2)	2	1.43	0.77	2.65	0.26
	8 weeks (standard 1)	9	2.73	2.04	3.64	< 0.00001
	8 weeks (standard 2)	4	2.36	1.59	3.5	< 0.0001
Effective rate in ECG improvement	4 weeks	5	1.49	1.07	2.08	0.02
	6 weeks	3	2.47	1.6	3.82	< 0.0001
	8 weeks	11	3.44	2.7	4.39	< 0.00001
Markedly effective rate in ECG improvement	4 weeks	5	1.62	1.07	2.47	0.02
	6 weeks	3	2.34	1.4	3.9	0.001
	8 weeks	11	2.37	1.76	3.18	< 0.00001
Adverse drug reactions	_	23	0.12	0.09	0.17	< 0.00001



Meta-analyses on markedly effective rate in symptom improvement (standard 1).

2.6. Statistical analysis

Odds ratio (OR) with 95% confidence intervals (CIs) was used to estimate the effect size for the dichotomous variables. The metaanalysis with the random-effect model as the primary analysis was conducted by Review Manager 5.4.1 software. Then, the metaanalysis with the fixed-effect model was conducted as the sensitivity analysis. P < 0.05 indicated a statistically significant difference between the two groups. Subgroup analyses were conducted based on the duration. The publication bias was assessed by the funnel plot. The level of evidence for each outcome was assessed by the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system.

3. Results

3.1. Literature search

This systematic review identified 1,385 potentially eligible studies via the extensive search. Nine hundred and thirty-three duplicate studies were removed using EndNote software. Then, 396 irrelevant studies were deleted by checking the titles and abstracts. After checking fulltexts, 29 studies were finally included for the statistical analysis. The process of screening eligible studies is described in **Figure 1** (15–43).

3.2. Characteristics of included studies

The characteristics of the included studies are summarized in **Table 1**. They involved 3,185 patients and were published between 1997 and 2013. Sample size ranged from 25 to 120 in the experimental group and 25–114 in the control group. Isosorbide nitrate was used in 7 trials (15, 16, 19, 21, 23, 24, 42), and isosorbide dinitrate was used in other studies. There was the same dosage of CDDP or nitrates across the included studies. The duration of CDDP or nitrates ranged from 4 weeks to 12 weeks. However, patients took CDDP or nitrates with the same duration in the same study. Twenty-two RCTs reported the effective rate and the markedly effective rate in symptom improvement (17, 19–23, 26, 27, 29–42). Fifteen RCTs reported the effective rate and the markedly effective rate in ECG improvement (17, 22, 24, 26, 27, 29, 31–34, 36–39, 42). Twenty-three RCTs reported the adverse drug reactions (15–26, 28, 30, 32, 33, 35, 38–43).

3.3. Assessment of risk of bias

Figures 2, 3 show the results of risk of bias assessment. The risk of selection bias was graded as unclear in all of the included studies because no specific random sequence generation and

Study or Subgroup	CDD Events		Nitrat Events		Weight	Odds Ratio M-H, Random, 95% Cl	Odds Ratio M-H, Random, 95% Cl	
About 4 weeks	2101110	. ettai	210110	. etta	o / jin			_
Chi 2007	38	120	34	114	25.8%	1.09 [0.63, 1.90]	_ _	
_uo 2008	36	54	26	52	14.1%	2.00 [0.91, 4.38]		
3hi 2001	62	102	27	51	18.3%	1.38 [0.70, 2.72]	_ + •	
an 2001	29	40	18	40	10.3%	3.22 [1.27, 8.19]	- _	
'ue 2008	38	55	27	53	14.1%	2.15 [0.98, 4.72]		
(hang 1999	44	69	38	64	17.4%	1.20 [0.60, 2.42]		
Subtotal (95% CI)		440		374	100.0%	1.55 [1.14, 2.11]	◆	
otal events	247		170					
leterogeneity: Tau ² :	= 0.02; Ch	i ² = 5.59	9, df = 5 (P = 0.3	5); I² = 11	%		
est for overall effect								
bout 6 weeks								
.i 2006	32	56	26	50		1.23 [0.57, 2.65]		
'an 2008	16	50	6	30	33.8%	1.88 [0.64, 5.51]		
Subtotal (95% CI)		106		80	100.0%	1.42 [0.76, 2.65]	-	
otal events	48		32					
Heterogeneity: Tau ²				P = 0.5	3); l² = 09	6		
Fest for overall effect	: Z = 1.10	(P = 0.2	(7)					
lbout 8 weeks								
Deng 2002	19	56	5	30	12.7%	2.57 [0.85, 7.78]		
)ing 1999	36	52	26	50	23.7%	2.08 [0.92, 4.66]		
.u 2001	43	60	31	60	27.2%	2.37 [1.11, 5.04]	_ _	
	57	80	40	80	36.4%	2.48 [1.29, 4.76]	_ 	
Subtotal (95% CI)		248			100.0%	2.36 [1.59, 3.50]	•	
otal events	155		102					
Heterogeneity: Tau ² :	= 0.00; Ch	i ^z = 0.14	4, df = 3 (P = 0.9	9); Iz = 09	6		
est for overall effect	: Z = 4.26	(P < 0.0	001)					
							Nitrate CDDP	.0
Test for subaroup di	fferences:	Chi ² = 3	3.20. df =	2 (P =	0.20). I ² =	37.5%		

Frontiers in Cardiovascular Medicine

allocation concealment methods were reported. The risk of performance bias was also classified as unclear in all of the included studies because no blinding of participants, personnel or outcome assessment was clearly reported. The risk of attrition bias was low in all of the included studies due to the complete outcome data. The reporting bias and other bias were categorized as unclear risk because of the insufficient information.

3.4. Symptom improvement

3.4.1. Effective rate in symptom improvement

Twenty-two RCTs reported the effective rate in symptom improvement. The meta-analyses with the random-effect model indicated that CDDP could significantly increase the effective rate in symptom improvement compared with nitrates (Pooled 9 RCTs, OR = 1.95, 95% CI: 1.25–3.05, P = 0.003, duration of about

4 weeks; Pooled 4 RCTs, OR = 3.45, 95% CI: 1.84–6.48, P = 0.0001, duration of about 6 weeks; Pooled 13 RCTs, OR = 4.02, 95% CI: 2.14–7.57, P < 0.0001, duration of about 8 weeks; Figure 4). The results of the meta-analyses with fixed-effect model were similar with above results in Table 2. In addition, one RCT (29) reported that the effective rate in symptom improvement in the CDDP group was higher than that in the nitrates group (OR = 1.5, 95% CI: 0.68–3.31, P = 0.32) after 5 weeks of CDDP treatment.

3.4.2. Markedly effective rate in symptom improvement

Twenty-two RCTs reported the markedly effective rate in symptom improvement. When the markedly effective in symptom improvement was defined as "symptoms associated with SAP were disappeared, the frequency of angina attacks or nitroglycerin consumption was reduced by more than 80% after

	CDDF		Nitrat		Mojabt	Odds Ratio M-H, Random, 95% Cl	Odds Ratio M-H, Random, 95% Cl
Study or Subgroup 6.1.1 About 4 weeks	Events	Total	Events	Total	weight	M-H, Kandom, 95% CI	M-H, Kandom, 95% Ci
	74	400	70		22.00	0.04/0.65.4.60	
Chi 2007	74	120	72	114	32.0%	0.94 [0.55, 1.59]	
Dong 2001	17	30	9	30	13.8%	3.05 [1.05, 8.84]	
Guo 2001	20	25	16	25	10.4%	2.25 [0.63, 8.06]	
Tan 2001	26	40	23	40	17.5%	1.37 [0.56, 3.39]	
Xue 2001	81	102	58	90	26.4%	2.13 [1.12, 4.06]	
Subtotal (95% CI)		317		299	100.0 %	1.60 [1.02, 2.52]	
Total events	218		178				
Heterogeneity: Tau ² =				P = 0.1	8); I ^z = 36	%	
Test for overall effect:	Z= 2.04 (P = 0.0)4)				
6.1.2 About 6 weeks							
Guo 2001	18	25	14	25	13.6%	2.02 [0.62, 6.56]	
Li 2005	48	70	26	60	36.5%	2.85 [1.39, 5.85]	─■ ──
Xue 2001	77	102	51	90	49.9%	2.36 [1.27, 4.35]	_ _ ∎
Subtotal (95% CI)		197			100.0%	2.47 [1.60, 3.82]	•
Total events	143		91				
Heterogeneity: Tau ² =		2 =02		P = 0.8	$7) \cdot I^2 = 0.9$	6	
Test for overall effect:	•			0.0	17,1 = 07	•	
restion overall ellect.	2 - 4.03 (1 - 0.0	,001)				
6.1.3 About 8 weeks							
Chu 2003	22	35	13	32	6.2%	2.47 [0.92, 6.62]	
Gao 2000	42	60	14	60	9.1%	7.67 [3.40, 17.30]	_
Guo 2001	20	25	13	25	3.8%	3.69 [1.05, 12.96]	
Guo 2001 Lu 2001	20 38	25 60			3.8% 11.0%	3.69 [1.05, 12.96] 2.78 [1.33, 5.82]	
			13	25		• • •	
Lu 2001	38	60	13 23	25 60	11.0%	2.78 [1.33, 5.82]	
Lu 2001 Wang 2003 Xue 2001	38 46	60 52	13 23 30	25 60 50	11.0% 5.8%	2.78 [1.33, 5.82] 5.11 [1.84, 14.20] 3.59 [1.93, 6.69]	
Lu 2001 Wang 2003	38 46 79	60 52 102	13 23 30 44	25 60 50 90	11.0% 5.8% 15.6%	2.78 [1.33, 5.82] 5.11 [1.84, 14.20] 3.59 [1.93, 6.69] 4.38 [1.63, 11.74]	
Lu 2001 Wang 2003 Xue 2001 Yang 2001 Yao 2002 a	38 46 79 35 40	60 52 102 43 50	13 23 30 44 20 25	25 60 50 90 40 50	11.0% 5.8% 15.6% 6.2% 7.6%	2.78 [1.33, 5.82] 5.11 [1.84, 14.20] 3.59 [1.93, 6.69] 4.38 [1.63, 11.74] 4.00 [1.65, 9.72]	
Lu 2001 Wang 2003 Xue 2001 Yang 2001	38 46 79 35	60 52 102 43	13 23 30 44 20	25 60 50 90 40	11.0% 5.8% 15.6% 6.2%	2.78 [1.33, 5.82] 5.11 [1.84, 14.20] 3.59 [1.93, 6.69] 4.38 [1.63, 11.74] 4.00 [1.65, 9.72] 2.04 [0.71, 5.89]	
Lu 2001 Wang 2003 Xue 2001 Yang 2001 Yao 2002 a Zhang 2009 Zhou 1998	38 46 79 35 40 21	60 52 102 43 50 30	13 23 30 44 20 25 16	25 60 50 90 40 50 30	11.0% 5.8% 15.6% 6.2% 7.6% 5.4% 14.7%	2.78 [1.33, 5.82] 5.11 [1.84, 14.20] 3.59 [1.93, 6.69] 4.38 [1.63, 11.74] 4.00 [1.65, 9.72] 2.04 [0.71, 5.89] 2.78 [1.47, 5.27]	
Lu 2001 Wang 2003 Xue 2001 Yang 2001 Yao 2002 a Zhang 2009 Zhou 1998 Zhu 2001	38 46 79 35 40 21 76	60 52 102 43 50 30 120	13 23 30 44 20 25 16 23	25 60 90 40 50 30 60 80	11.0% 5.8% 15.6% 6.2% 7.6% 5.4%	2.78 [1.33, 5.82] 5.11 [1.84, 14.20] 3.59 [1.93, 6.69] 4.38 [1.63, 11.74] 4.00 [1.65, 9.72] 2.04 [0.71, 5.89] 2.78 [1.47, 5.27] 2.78 [1.46, 5.27]	
Lu 2001 Wang 2003 Xue 2001 Yang 2001 Yao 2002 a Zhang 2009 Zhou 1998 Zhu 2001 Subtotal (95% Cl)	38 46 79 35 40 21 76 50	60 52 102 43 50 30 120 80	13 23 30 44 20 25 16 23 30	25 60 90 40 50 30 60 80	11.0% 5.8% 15.6% 6.2% 7.6% 5.4% 14.7% 14.7%	2.78 [1.33, 5.82] 5.11 [1.84, 14.20] 3.59 [1.93, 6.69] 4.38 [1.63, 11.74] 4.00 [1.65, 9.72] 2.04 [0.71, 5.89] 2.78 [1.47, 5.27]	
Lu 2001 Wang 2003 Xue 2001 Yang 2001 Yao 2002 a Zhang 2009 Zhou 1998 Zhu 2001 Subtotal (95% CI) Total events	38 46 79 35 40 21 76 50 469	60 52 102 43 50 30 120 80 657	13 23 30 44 20 25 16 23 30 251	25 60 90 40 50 30 60 80 577	11.0% 5.8% 15.6% 6.2% 7.6% 5.4% 14.7% 14.7% 100.0 %	2.78 [1.33, 5.82] 5.11 [1.84, 14.20] 3.59 [1.93, 6.69] 4.38 [1.63, 11.74] 4.00 [1.65, 9.72] 2.04 [0.71, 5.89] 2.78 [1.47, 5.27] 2.78 [1.46, 5.27] 3.43 [2.68, 4.38]	
Lu 2001 Wang 2003 Xue 2001 Yang 2001 Yao 2002 a Zhang 2009 Zhou 1998 Zhu 2001 Subtotal (95% CI) Total events Heterogeneity: Tau ² =	38 46 79 35 40 21 76 50 469 : 0.00; Chi	60 52 102 43 50 30 120 80 657 ² = 7.2	13 23 30 44 20 25 16 23 30 251 1, df = 10	25 60 90 40 50 30 60 80 577	11.0% 5.8% 15.6% 6.2% 7.6% 5.4% 14.7% 14.7% 100.0 %	2.78 [1.33, 5.82] 5.11 [1.84, 14.20] 3.59 [1.93, 6.69] 4.38 [1.63, 11.74] 4.00 [1.65, 9.72] 2.04 [0.71, 5.89] 2.78 [1.47, 5.27] 2.78 [1.46, 5.27] 3.43 [2.68, 4.38]	
Lu 2001 Wang 2003 Xue 2001 Yang 2001 Yao 2002 a Zhang 2009 Zhou 1998 Zhu 2001 Subtotal (95% CI) Total events	38 46 79 35 40 21 76 50 469 : 0.00; Chi	60 52 102 43 50 30 120 80 657 ² = 7.2	13 23 30 44 20 25 16 23 30 251 1, df = 10	25 60 90 40 50 30 60 80 577	11.0% 5.8% 15.6% 6.2% 7.6% 5.4% 14.7% 14.7% 100.0 %	2.78 [1.33, 5.82] 5.11 [1.84, 14.20] 3.59 [1.93, 6.69] 4.38 [1.63, 11.74] 4.00 [1.65, 9.72] 2.04 [0.71, 5.89] 2.78 [1.47, 5.27] 2.78 [1.46, 5.27] 3.43 [2.68, 4.38]	
Lu 2001 Wang 2003 Xue 2001 Yang 2001 Yao 2002 a Zhang 2009 Zhou 1998 Zhu 2001 Subtotal (95% CI) Total events Heterogeneity: Tau ² =	38 46 79 35 40 21 76 50 469 : 0.00; Chi	60 52 102 43 50 30 120 80 657 ² = 7.2	13 23 30 44 20 25 16 23 30 251 1, df = 10	25 60 90 40 50 30 60 80 577	11.0% 5.8% 15.6% 6.2% 7.6% 5.4% 14.7% 14.7% 100.0 %	2.78 [1.33, 5.82] 5.11 [1.84, 14.20] 3.59 [1.93, 6.69] 4.38 [1.63, 11.74] 4.00 [1.65, 9.72] 2.04 [0.71, 5.89] 2.78 [1.47, 5.27] 2.78 [1.46, 5.27] 3.43 [2.68, 4.38]	
Lu 2001 Wang 2003 Xue 2001 Yang 2001 Yao 2002 a Zhang 2009 Zhou 1998 Zhu 2001 Subtotal (95% CI) Total events Heterogeneity: Tau ² =	38 46 79 35 40 21 76 50 469 : 0.00; Chi	60 52 102 43 50 30 120 80 657 ² = 7.2	13 23 30 44 20 25 16 23 30 251 1, df = 10	25 60 90 40 50 30 60 80 577	11.0% 5.8% 15.6% 6.2% 7.6% 5.4% 14.7% 14.7% 100.0 %	2.78 [1.33, 5.82] 5.11 [1.84, 14.20] 3.59 [1.93, 6.69] 4.38 [1.63, 11.74] 4.00 [1.65, 9.72] 2.04 [0.71, 5.89] 2.78 [1.47, 5.27] 2.78 [1.46, 5.27] 3.43 [2.68, 4.38]	
Lu 2001 Wang 2003 Xue 2001 Yang 2001 Yao 2002 a Zhang 2009 Zhou 1998 Zhu 2001 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect:	38 46 79 35 40 21 76 50 469 0.00; Chi Z = 9.85 (60 52 102 43 50 120 80 657 ² = 7.2 P < 0.0	13 23 30 44 20 25 16 23 30 251 1, df = 10 00001)	25 60 50 90 40 50 30 60 80 577 (P = 0.	11.0% 5.8% 15.6% 6.2% 7.6% 5.4% 14.7% 100.0% 71); I ² = 0	2.78 [1.33, 5.82] 5.11 [1.84, 14.20] 3.59 [1.93, 6.69] 4.38 [1.63, 11.74] 4.00 [1.65, 9.72] 2.04 [0.71, 5.89] 2.78 [1.47, 5.27] 2.78 [1.46, 5.27] 3.43 [2.68, 4.38] %	0.01 0.1 1 10 100 Nitrate CDDP
Lu 2001 Wang 2003 Xue 2001 Yang 2001 Yao 2002 a Zhang 2009 Zhou 1998 Zhu 2001 Subtotal (95% CI) Total events Heterogeneity: Tau ² =	38 46 79 35 40 21 76 50 469 0.00; Chi Z = 9.85 (60 52 102 43 50 120 80 657 ² = 7.2 P < 0.0	13 23 30 44 20 25 16 23 30 251 1, df = 10 00001)	25 60 50 90 40 50 30 60 80 577 (P = 0.	11.0% 5.8% 15.6% 6.2% 7.6% 5.4% 14.7% 100.0% 71); I ² = 0	2.78 [1.33, 5.82] 5.11 [1.84, 14.20] 3.59 [1.93, 6.69] 4.38 [1.63, 11.74] 4.00 [1.65, 9.72] 2.04 [0.71, 5.89] 2.78 [1.47, 5.27] 2.78 [1.46, 5.27] 3.43 [2.68, 4.38] %	

Church and Carls and	CDDP	0	Nitrat	е		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
About 4 weeks							
Chi 2007	16	120	12	114	27.6%	1.31 [0.59, 2.90]	
Dong 2001	6	30	4	30	9.2%	1.63 [0.41, 6.47]	
Guo 2001	6	25	4	25	8.8%	1.66 [0.41, 6.78]	
Tan 2001	19	40	13	40	21.3%	1.88 [0.76, 4.65]	+
Xue 2001	25	102	14	90	33.1%	1.76 [0.85, 3.65]	+
Subtotal (95% CI)		317		299	100.0%	1.62 [1.07, 2.47]	◆
Total events	72		47				
Heterogeneity: Tau ² =	= 0.00; Chi	² = 0.43	3, df = 4 (l	P = 0.9	8); I ² = 0%	6	
Test for overall effect:					,,		
About 6 weeks							
Guo 2001	6	25	4	25	13.3%	1.66 [0.41, 6.78]	
Li 2005	28	70	10	60	38.4%	3.33 [1.45, 7.65]	─-■
Xue 2001	25	102	13	90	48.3%	1.92 [0.92, 4.03]	+ -
Subtotal (95% CI)		197		175	100.0%	2.33 [1.39, 3.90]	●
Total events	59		27				
Heterogeneity: Tau ² =	= 0.00; Chi ²	² =1.2), df = 2 (l	P = 0.5	5); I ^z = 0%	6	
Test for overall effect:	Z = 3.22 (P = 0.0	01)				
About 8 weeks							
Chu 2003	7	35	4	32	5.0%	1.75 [0.46, 6.65]	
Gao 2000	18	60	6	60	8.7%	3.86 [1.41, 10.57]	
Guo 2001	7	25	3	25	4.0%	2.85 [0.64, 12.64]	
Lu 2001	14	60	8	60	9.7%	1.98 [0.76, 5.14]	+
Wang 2003	32	52	24	50	14.3%	1.98 [0.76, 5.14] 1.73 [0.79, 3.81]	
Wang 2003 Xue 2001	32 27	52 102	24 9	50 90	14.3% 13.2%	1.73 [0.79, 3.81] 3.24 [1.43, 7.34]	
Wang 2003 Xue 2001 Yang 2001	32 27 13	52 102 43	24 9 5	50	14.3% 13.2% 6.8%	1.73 [0.79, 3.81]	
Wang 2003 Xue 2001 Yang 2001 Yao 2002 a	32 27 13 15	52 102 43 50	24 9 5 5	50 90 40 50	14.3% 13.2% 6.8% 7.3%	1.73 [0.79, 3.81] 3.24 [1.43, 7.34] 3.03 [0.97, 9.49] 3.86 [1.28, 11.64]	
Wang 2003 Xue 2001 Yang 2001 Yao 2002 a Zhang 2009	32 27 13 15 9	52 102 43 50 30	24 9 5 5 7	50 90 40 50 30	14.3% 13.2% 6.8% 7.3% 6.7%	1.73 [0.79, 3.81] 3.24 [1.43, 7.34] 3.03 [0.97, 9.49] 3.86 [1.28, 11.64] 1.41 [0.45, 4.45]	
Wang 2003 Xue 2001 Yang 2001 Yao 2002 a Zhang 2009 Zhou 1998	32 27 13 15 9 28	52 102 43 50 30 120	24 9 5 5 7 8	50 90 40 50 30 60	14.3% 13.2% 6.8% 7.3% 6.7% 12.1%	1.73 [0.79, 3.81] 3.24 [1.43, 7.34] 3.03 [0.97, 9.49] 3.86 [1.28, 11.64] 1.41 [0.45, 4.45] 1.98 [0.84, 4.66]	
Wang 2003 Xue 2001 Yang 2001 Yao 2002 a Zhang 2009 Zhou 1998 Zhu 2001	32 27 13 15 9	52 102 43 50 30 120 80	24 9 5 5 7	50 90 40 50 30 60 80	14.3% 13.2% 6.8% 7.3% 6.7% 12.1% 12.4%	1.73 [0.79, 3.81] 3.24 [1.43, 7.34] 3.03 [0.97, 9.49] 3.86 [1.28, 11.64] 1.41 [0.45, 4.45] 1.98 [0.84, 4.66] 2.03 [0.87, 4.73]	
Wang 2003 Xue 2001 Yang 2001 Yao 2002 a Zhang 2009 Zhou 1998 Zhu 2001 Subtotal (95% Cl)	32 27 13 15 9 28 18	52 102 43 50 30 120	24 9 5 7 8 10	50 90 40 50 30 60 80	14.3% 13.2% 6.8% 7.3% 6.7% 12.1%	1.73 [0.79, 3.81] 3.24 [1.43, 7.34] 3.03 [0.97, 9.49] 3.86 [1.28, 11.64] 1.41 [0.45, 4.45] 1.98 [0.84, 4.66]	
Wang 2003 Xue 2001 Yang 2001 Yao 2002 a Zhang 2009 Zhou 1998 Zhu 2001 Subtotal (95% CI) Total events	32 27 13 15 9 28 18 18	52 102 43 50 30 120 80 657	24 9 5 7 8 10	50 90 40 50 30 60 80 577	14.3% 13.2% 6.8% 7.3% 6.7% 12.1% 12.4% 100.0%	1.73 [0.79, 3.81] 3.24 [1.43, 7.34] 3.03 [0.97, 9.49] 3.86 [1.28, 11.64] 1.41 [0.45, 4.45] 1.98 [0.84, 4.66] 2.03 [0.87, 4.73] 2.35 [1.74, 3.16]	
Wang 2003 Xue 2001 Yang 2001 Yao 2002 a Zhang 2009 Zhou 1998 Zhu 2001 Subtotal (95% CI) Total events Heterogeneity: Tau ² =	32 27 13 15 9 28 18 18 = 0.00; Chi ²	52 102 43 50 30 120 80 657 ² = 4.4	24 9 5 7 8 10 89 7, df = 10	50 90 40 50 30 60 80 577	14.3% 13.2% 6.8% 7.3% 6.7% 12.1% 12.4% 100.0%	1.73 [0.79, 3.81] 3.24 [1.43, 7.34] 3.03 [0.97, 9.49] 3.86 [1.28, 11.64] 1.41 [0.45, 4.45] 1.98 [0.84, 4.66] 2.03 [0.87, 4.73] 2.35 [1.74, 3.16]	
Wang 2003 Xue 2001 Yang 2001 Yao 2002 a Zhang 2009 Zhou 1998 Zhu 2001 Subtotal (95% CI) Total events	32 27 13 15 9 28 18 18 = 0.00; Chi ²	52 102 43 50 30 120 80 657 ² = 4.4	24 9 5 7 8 10 89 7, df = 10	50 90 40 50 30 60 80 577	14.3% 13.2% 6.8% 7.3% 6.7% 12.1% 12.4% 100.0%	1.73 [0.79, 3.81] 3.24 [1.43, 7.34] 3.03 [0.97, 9.49] 3.86 [1.28, 11.64] 1.41 [0.45, 4.45] 1.98 [0.84, 4.66] 2.03 [0.87, 4.73] 2.35 [1.74, 3.16]	
Wang 2003 Xue 2001 Yang 2001 Yao 2002 a Zhang 2009 Zhou 1998 Zhu 2001 Subtotal (95% CI) Total events Heterogeneity: Tau ² =	32 27 13 15 9 28 18 18 = 0.00; Chi ²	52 102 43 50 30 120 80 657 ² = 4.4	24 9 5 7 8 10 89 7, df = 10	50 90 40 50 30 60 80 577	14.3% 13.2% 6.8% 7.3% 6.7% 12.1% 12.4% 100.0%	1.73 [0.79, 3.81] 3.24 [1.43, 7.34] 3.03 [0.97, 9.49] 3.86 [1.28, 11.64] 1.41 [0.45, 4.45] 1.98 [0.84, 4.66] 2.03 [0.87, 4.73] 2.35 [1.74, 3.16]	
Wang 2003 Xue 2001 Yang 2001 Yao 2002 a Zhang 2009 Zhou 1998 Zhu 2001 Subtotal (95% CI) Total events Heterogeneity: Tau ² =	32 27 13 15 9 28 18 18 = 0.00; Chi ²	52 102 43 50 30 120 80 657 ² = 4.4	24 9 5 7 8 10 89 7, df = 10	50 90 40 50 30 60 80 577	14.3% 13.2% 6.8% 7.3% 6.7% 12.1% 12.4% 100.0%	1.73 [0.79, 3.81] 3.24 [1.43, 7.34] 3.03 [0.97, 9.49] 3.86 [1.28, 11.64] 1.41 [0.45, 4.45] 1.98 [0.84, 4.66] 2.03 [0.87, 4.73] 2.35 [1.74, 3.16]	
Wang 2003 Xue 2001 Yang 2001 Yao 2002 a Zhang 2009 Zhou 1998 Zhu 2001 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect:	32 27 13 15 9 28 18 18 = 0.00; Chi ^a : Z = 5.63 (I	52 102 43 50 30 120 80 657 ² = 4.47 P < 0.0	24 9 5 7 8 10 89 7, df = 10 0001)	50 90 40 50 30 60 80 577 (P = 0.	14.3% 13.2% 6.8% 7.3% 6.7% 12.1% 12.4% 100.0% 92); I ² = 0	1.73 [0.79, 3.81] 3.24 [1.43, 7.34] 3.03 [0.97, 9.49] 3.86 [1.28, 11.64] 1.41 [0.45, 4.45] 1.98 [0.84, 4.66] 2.03 [0.87, 4.73] 2.35 [1.74, 3.16]	0.01 0.1 1 10 100 Nitrate CDDP
Wang 2003 Xue 2001 Yang 2001 Yao 2002 a Zhang 2009 Zhou 1998 Zhu 2001 Subtotal (95% CI) Total events Heterogeneity: Tau ² =	32 27 13 15 9 28 18 18 = 0.00; Chi ^a : Z = 5.63 (I	52 102 43 50 30 120 80 657 ² = 4.47 P < 0.0	24 9 5 7 8 10 89 7, df = 10 0001)	50 90 40 50 30 60 80 577 (P = 0.	14.3% 13.2% 6.8% 7.3% 6.7% 12.1% 12.4% 100.0% 92); I ² = 0	1.73 [0.79, 3.81] 3.24 [1.43, 7.34] 3.03 [0.97, 9.49] 3.86 [1.28, 11.64] 1.41 [0.45, 4.45] 1.98 [0.84, 4.66] 2.03 [0.87, 4.73] 2.35 [1.74, 3.16]	

treatment" (standard 1), the meta-analyses with the random-effect model indicated that CDDP compared with nitrates could increase the markedly effective rate in symptom improvement with no statistical significance at 4 and 6 weeks after treatment (Pooled 3 RCTs, OR = 1.26, 95% CI: 0.75-2.10, P = 0.38, duration of about 4 weeks; Pooled 2 RCTs, OR = 1.56, 95% CI: 0.86-2.81, P = 0.14, duration of about 6 weeks; Figure 5) and with the statistical significance at 8 weeks after treatment (Pooled 9 RCTs, OR = 2.63, 95% CI: 1.70-4.05, P < 0.0001, duration of about 8 weeks; Figure 5). When the markedly effective in symptom improvement was defined as "symptoms associated with SAP were disappeared, the frequency of angina attacks or nitroglycerin consumption was reduced by more than 90% after treatment" (standard 2), the meta-analyses with the randomeffect model indicated that CDDP compared with nitrates could increase the markedly effective rate in symptom improvement with no statistical significance at 6 weeks after treatment (Pooled 2 RCTs, OR = 1.42, 95% CI: 0.76-2.65, P = 0.27, duration of about 6 weeks; Figure 6) and with the statistical significance at 4 and 8 weeks after treatment (Pooled 6 RCTs, OR = 1.55, 95% CI: 1.14–2.11, P = 0.005, duration of about 4 weeks; Pooled 4 RCTs, OR = 2.36, 95% CI: 1.59-3.50, P < 0.0001, duration of about 8 weeks; Figure 6). The results of the meta-analyses with fixedeffect model were similar with above results in Table 2.

3.5. ECG improvement

3.5.1. Effective rate in ECG improvement

Fifteen RCTs reported the effective rate in ECG improvement. The meta-analyses with the random-effect model indicated that CDDP could significantly increase the effective rate in ECG improvement compared with nitrates (Pooled 5 RCTs, OR = 1.60, 95% CI: 1.02-2.52, P = 0.04, duration of about 4 weeks; Pooled 3 RCTs, OR = 2.47, 95% CI: 1.60-3.82, P < 0.0001, duration of about 6 weeks; Pooled 11 RCTs, OR = 3.43, 95% CI: 2.68-4.38,

P < 0.00001, duration of about 8 weeks; Figure 7). The results of the meta-analyses with fixed-effect model were similar with above results in Table 2.

3.5.2. Markedly effective rate in ECG improvement

Fifteen RCTs reported the markedly effective rate in ECG improvement. The meta-analyses with the random-effect model indicated that CDDP could significantly increase the markedly effective rate in ECG improvement compared with nitrates (Pooled 5 RCTs, OR = 1.62, 95% CI: 1.07-2.47, P = 0.02, duration of about 4 weeks; Pooled 3 RCTs, OR = 2.33, 95% CI: 1.39-3.90, P = 0.001, duration of about 6 weeks; Pooled 11 RCTs, OR = 2.35, 95% CI: 1.74-3.16, P < 0.00001, duration of about 8 weeks; **Figure 8**). The results of the meta-analyses with fixed-effect model were similar with above results in **Table 2**.

3.6. Adverse drug reactions

Twenty-three RCTs reported the adverse drug reactions. The pooled result showed that the incidence of adverse drug reactions in the CDDP group was lower than that in the nitrates group (Pooled 23 RCTs, OR = 0.15, 95% CI: 0.1–0.21, P < 0.00001, Figure 9). Specifically, adverse drug reactions included stomach discomfort in the CDDP group. In the nitrate group, adverse drug reactions included headache, dizziness, facial burning, nausea, etc.

3.7. Publication bias

Funnel plots of the meta-analyses are presented in **Figure 10**. Publication bias may be existed because of the asymmetry in some funnel plots. It may be associated with small sample size, poor methodological quality, etc.


3.8. Grade of evidence

The grade of evidence for each outcome was presented in **Table 3**. The levels of the evidence for the effective rate and the markedly effective rate in symptom improvement ranged from very low to low. The levels of the evidence for the effective rate and markedly effective rate in ECG improvement were classified as low.

4. Discussion

Nitrates have been widely used in the management of angina in the clinical practice (44). However, the long-term use of nitrates may be limited because of the tolerance to nitrates (44). It may be caused by multiple factors, such as a burst of oxygen free radicals and vascular peroxynitrite formation (45–47). Many efforts are made to reduce the tolerance to nitrates, such as the intermittent nitrate therapy and long-acting nitrates (48). However, intermittent nitrate therapy may bring about the

Chudu or Cubarcon	CDD	-	Nitrat		Maint	Odds Ratio	Odds Ratio		
Study or Subgroup						M-H, Random, 95% Cl	M-H, Random, 95% Cl		
Chi 2007	8	120	32	114	15.4%	0.18 [0.08, 0.42]			
Deng 2002	0	56	9	30	1.5%	0.02 [0.00, 0.36]			
Ding 1999	2	52	13	50	5.1%	0.11 [0.02, 0.54]			
Dong 2001	0	30	6	30	1.5%	0.06 [0.00, 1.15]			
Gao 2000	3	60	5	60	5.5%	0.58 [0.13, 2.54]			
Gong 2013	0	60	6	60	1.5%	0.07 [0.00, 1.26]			
Huang 2004	2	40	13	38	4.9%	0.10 [0.02, 0.49]			
Li 2005	0	70	8	60	1.5%	0.04 [0.00, 0.78]			
Li 2006	0	56	9	50	1.5%	0.04 [0.00, 0.68]			
Liu 1997	0	62	4	30	1.5%	0.05 [0.00, 0.91]			
Luo 2008	3	54	16	52	7.0%	0.13 [0.04, 0.49]			
Pan 2008	0	50	8	30	1.5%	0.03 [0.00, 0.47]			
Shao 2013	0	66	10	60	1.6%	0.04 [0.00, 0.63]			
Shi 2001	0	102	11	51	1.6%	0.02 [0.00, 0.30]	·		
Wang 2003	1	52	4	50	2.5%	0.23 [0.02, 2.09]			
Wang 2009	2	29	4	28	3.9%	0.44 [0.07, 2.65]			
Xue 2001	5	102	35	90	11.3%	0.08 [0.03, 0.22]	_ - _		
Yang 2001	2	43	6	40	4.4%	0.28 [0.05, 1.46]			
Yao 2002 b	0	50	18	50	1.6%	0.02 [0.00, 0.30]			
Yue 2008	4	55	16	53	8.4%	0.18 [0.06, 0.59]			
Zhang 1999	2	69	7	64	4.7%	0.24 [0.05, 1.22]			
Zhang 2009	3	30	5	30	5.2%	0.56 [0.12, 2.57]			
Zhou 1998	3	120	7	60	6.2%	0.19 [0.05, 0.78]			
Total (95% CI)		1428		1180	100.0%	0.15 [0.10, 0.21]	•		
Total events	40		252						
Heterogeneity: Tau² = Test for overall effect:				2 (P = (6%	0.001 0.1 1 10 100 CDDP Nitrate			



rebound ischemia (49), and long-acting nitrates may be associated with the endothelial dysfunction (48). At present, novel nitrate drugs are still under development (50, 51). Some side effects associated with nitrates for treating angina have been reported, such as headache, dizziness, and hypotension (52). Therefore, alternative therapies for angina are still needed. CDDP has been approved for treating angina associated with coronary heart disease by the National Medical Products Administration in China for over twenty years. Many RCTs comparing CDDP with nitrates for treating angina has been published in recent years. A systematic review in 2015 suggested that CDDP were more effective than isosorbide

TABLE 3 GRADE quality of evidence summary table.

Outcomes	Illustrative Comp	parative Risks (95% CI)	OR (95% CI)	No. of Participants	Quality of the
	Assumed Risk (Nitrates)	Corresponding Risk (CDDP)		(Studies)	Evidence
Effective rate in symptom improvement (CDDP for about 4 weeks)	844 per 1,000	913 per 1,000 (871-943)	1.95 (1.25-3.05)	1,116 (9 studies)	⊕⊕⊖⊖ Low*
Effective rate in symptom improvement (CDD for about 6 weeks)	759 per 1,000	916 per 1,000 (853–953)	3.45 (1.84-6.48)	428 (4 studies)	⊕⊕⊖⊖ Low*
Effective rate in symptom improvement (CDD for about 8 weeks)	756 per 1,000	926 per 1,000 (869–959)	4.02 (2.14-7.57)	1,422 (13 studies)	⊕⊖⊖⊖ Very low* ^{,†}
Markedly effective rate in symptom improvement (Srandard 1, CDDP for about 4 weeks)	241 per 1,000	286 per 1,000 (193-401)	1.26 (0.75–2.1)	302 (3 studies)	⊕⊕⊖⊖ Low*
Markedly effective rate in symptom improvement (Srandard 2, CDDP for about 4 weeks)	455 per 1,000	564 per 1,000 (487–637)	1.55 (1.14–2.11)	814 (6 studies)	⊕⊕⊖⊖ Low*
Markedly effective rate in symptom improvement (Srandard 1, CDDP for about 6 weeks)	209 per 1,000	291 per 1,000 (185-426)	1.56 (0.86–2.81)	242 (2 studies)	⊕⊕⊖⊖ Low*
Markedly effective rate in symptom improvement (Srandard 2, CDDP for about 6 weeks)	400 per 1,000	486 per 1,000 (336-639)	1.42 (0.76-2.65)	186 (2 studies)	⊕⊕⊖⊖ Low*
Markedly effective rate in symptom improvement (Srandard 1, CDDP for about 8 weeks)	318 per 1,000	551 per 1,000 (442-654)	2.63 (1.7-4.05)	954 (9 studies)	$\begin{array}{c} \oplus \Theta \Theta \\ \text{Very low}^{\star,\dagger} \end{array}$
Markedly effective rate in symptom improvement (Srandard 2, CDDP for about 8 weeks)	464 per 1,000	671 per 1,000 (579–752)	2.36 (1.59–3.5)	468 (4 studies)	⊕⊕⊖⊖ Low*
Effective rate in ECG improvement (CDDP for about 4 weeks)	595 per 1,000	702 per 1,000 (600–788)	1.60 (1.02-2.52)	616 (5 studies)	⊕⊕⊖⊖ Low*
Effective rate in ECG improvement (CDDP for about 6 weeks)	520 per 1,000	728 per 1,000 (634–805)	2.47 (1.60-3.82)	372 (3 studies)	⊕⊕⊖⊖ Low*
Effective rate in ECG improvement (CDDP for about 8 weeks)	435 per 1,000	725 per 1,000 (674–771)	3.43 (2.68-4.38)	1,234 (11 studies)	⊕⊕⊖⊖ Low*
Markedly effective rate in ECG improvement (CDDP for about 4 weeks)	157 per 1,000	232 per 1,000 (166-315)	1.62 (1.07–2.47)	616 (5 studies)	⊕⊕⊖⊖ Low*
Markedly effective rate in ECG improvement (CDDP for about 6 weeks)	154 per 1,000	298 per 1,000 (202-416)	2.33 (1.39-3.90)	372 (3 studies)	⊕⊕⊖⊖ Low*
Markedly effective rate in ECG improvement (CDDP for about 8 weeks)	154 per 1,000	300 per 1,000 (214-366)	2.35 (1.74-3.16)	1,234 (11 studies)	⊕⊕⊖⊖ Low*
Adverse drug reactions	214 per 1,000	39 per 1,000 (26-54)	0.15 (0.1-0.21)	2,608 (23 studies)	⊕⊕⊖⊖ Low*

CDDP, Compound danshen dropping pills; CI, Confidence interval; OR, Odds ratio.

^{*}Unclear risk of bias due to limitations of randomization, allocation concealment and blinding.

[†]I2 was more than 50%.

dinitrate in improving the symptoms and ECG in patients with angina (53). However, some limitations on that study can't be ignored. For example, only isosorbide dinitrate as one type of nitrates was considered as the control intervention. The safety was not assessed and the subgroup analysis based on stable and unstable angina was not conducted. Another systematic review in 2021 did not conduct subgroup analyses based on the duration of the drugs, and did not report adverse drug reactions (54). In this study, an updated systematic review with the strict eligibility criteria was conducted to critically evaluate the efficacy and safety of CDDP vs. nitrates for treating SAP. The meta-analyses were conducted based on the duration of CDDP. The pooled results showed that the effective rate in symptom improvement and ECG improvement were significantly increased at about 4, 6 or 8 weeks after CDDP treatment compared to nitrates. The incidence of adverse reactions in the CDDP group was lower than that in the nitrates group. It means that CDDP with the duration of at least 4 weeks has the relative advantages in relieving symptoms associated with SAP, reducing the frequency of angina attacks or nitroglycerin consumption, and has relatively fewer adverse effects compared with nitrates. It provides a new insight into the management of SAP. CDDP with the duration of at least 4 weeks may be considered as an alternative to nitrates for treating SAP.

Several limitations should be taken into consideration when interpreting above results. Firstly, the effect size may be overestimated or underestimated due to the small sample size (less than 100) in most of included studies. Secondly, the risks of selection bias, performance bias, reporting bias and other bias for most of included studies were graded as unclear because of insufficient information. Thirdly, the mechanisms of CDDP for treating SAP aren't fully understood due to the lack of pharmacological evidence.

5. Conclusion

The present study suggests that CDDP with the duration of at least 4 weeks can be considered as an alternative to nitrates for treating SAP. However, more high-quality RCTs are still needed to confirm these findings.

Data availability statement

The original contributions presented in the study are included in the article/**Supplementary Material**, further inquiries can be directed to the corresponding authors.

Author contributions

MZ: methodology, investigation, data curation, formal analysis, writing—original draft, writing—review and editing. WW: writing—original draft, writing—review and editing. HS: writing—original draft, writing—review and editing. JZ: conceptualization, methodology, investigation, data curation, writing—original draft, writing—review and editing. YH: conceptualization, methodology, investigation, data curation,

References

1. Ohman EM. Clinical practice. Chronic stable angina. N Engl J Med. (2016) 374 (12):1167–76. doi: 10.1056/NEJMcp1502240

2. Abbasi M, Neishaboury M, Koohpayehzadeh J, Etemad K, Meysamie A, Asgari F, et al. National prevalence of self-reported coronary heart disease and chronic stable angina pectoris: factor analysis of the underlying cardiometabolic risk factors in the SuRFNCD-2011. *Glob Heart*. (2018) 13(2):73–82 e1. doi: 10.1016/j. gheart.2018.01.001

3. Steg PG, Greenlaw N, Tendera M, Tardif JC, Ferrari R, Al-Zaibag M, et al. Prospective observational longitudinal registry of patients with stable coronary artery disease I. Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the international observational CLARIFY registry. *JAMA Intern Med.* (2014) 174(10):1651–9. doi: 10.1001/jamainternmed.2014.3773

4. Beatty AL, Spertus JA, Whooley MA. Frequency of angina pectoris and secondary events in patients with stable coronary heart disease (from the heart and soul study). *Am J Cardiol.* (2014) 114(7):997–1002. doi: 10.1016/j.amjcard.2014.07.009

5. Joshi PH, de Lemos JA. Diagnosis and management of stable angina: a review. JAMA. (2021) 325(17):1765-78. doi: 10.1001/jama.2021.1527

6. Wei J, Wu T, Yang Q, Chen M, Ni J, Huang D. Nitrates for stable angina: a systematic review and meta-analysis of randomized clinical trials. *Int J Cardiol.* (2011) 146(1):4–12. doi: 10.1016/j.ijcard.2010.05.019

7. Thadani U. Challenges with nitrate therapy and nitrate tolerance: prevalence, prevention, and clinical relevance. *Am J Cardiovasc Drugs*. (2014) 14(4):287–301. doi: 10.1007/s40256-014-0072-5

8. Chen W, Wang B, Ge Y, Xu H, Jiang C, Yu P, et al. A systematic review and meta-analysis of clinical research on treating angina pectoris of coronary heart disease with traditional Chinese medicine to promote blood circulation and remove blood stasis. *Ann Palliat Med.* (2021) 10(10):10506–14. doi: 10.21037/apm-21-2233

writing—original draft, writing—review and editing. All authors contributed to the article and approved the submitted version.

Conflict of interest

MZ, WW, HS and YH were employed by Tasly Pharmaceutical Group Co., Ltd. HS was also employed by Tasly Holding Group Co., Ltd.

The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2023. 1168730/full#supplementary-material.

9. Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application. *Chin J Nat Med.* (2013) 11(2):110–20. doi: 10.1016/S1875-5364(13)60037-0

10. Li S. Mapping ancient remedies: applying a network approach to traditional Chinese medicine. *Science*. (2015) 350(6262):S72–4.

11. Chen K, Chen M, Wang Q, Dong J, Ma S, Zhao X, et al. Potential molecular mechanism of compound danshen dripping pills in treatment of angina pectoris based on network pharmacology and molecular docking. *Yaowu Pingjia Yanjiu.* (2022) 45(7):1282–93.

12. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Br Med J.* (2021) 372:n71. doi: 10.1136/bmj.n71

13. Archbold RA. Comparison between national institute for health and care excellence (NICE) and European society of cardiology (ESC) guidelines for the diagnosis and management of stable angina: implications for clinical practice. *Open Heart.* (2016) 3(1):e000406. doi: 10.1136/openhrt-2016-000406

14. Li S, Wang R, Zhang Y, Zhang X, Layon AJ, Li Y, et al. Symptom combinations associated with outcome and therapeutic effects in a cohort of cases with SARS. *Am J Chin Med (Gard City N Y).* (2006) 34(6):937–47. doi: 10.1142/S0192415X06004417

15. Shao Z, Ji L, Zhang H. Effect of compound danshen dripping pills on stable angina pectoris. *People's Military Surgeon*. (2013) 56(4):423–4.

16. Gong L. Curative effect of compound danshen dripping pills on 60 cases of stable angina pectoris. *Chin J Geriatr Care.* (2013) 11(2):54–5. doi: 10.3969/j.issn. 1672-4860.2013.02.028

17. Zhang S. Therapeutic effect of compound danshen dripping pills on stable angina pectoris in the elderly. *J Changchun Univ Chin.* (2009) 25(1):89. doi: 10. 1007/s11802-009-0089-6

18. Wang J. Curative effect of compound dashhen dripping pills on 29 cases of stable angina pectoris. J Shanxi Univ Chin Med. (2009) 10(2):32–3. doi: 10.3969/j. issn.1671-0258.2009.02.013

19. Yue X. Effect of compound danshen dripping pills on stable angina pectoris of coronary heart disease. J Mod Med Health. (2008) 24(19):2888–9.

20. Pan C. Effect of compound Salvia miltiorrhiza dripping pills on stable angina pectoris. *Tianjin Pharm.* (2008) 20(4):56-7. doi: 10.3969/j.issn.1006-5687. 2008.04.029

21. Luo J. Clinical observation of compound danshen dripping pills in the treatment of stable angina pectoris. *China Med Her.* (2008) 5(22):82. doi: 10.3969/j.issn.1673-7210.2008.22

22. Chi B, He T, Yang Y. Treatment of 120 cases of stable angina pectoris with compound danshen dripping pills. *Shaanxi J Tradit Chin Med.* (2007) 28 (10):1283–5. doi: 10.3969/j.issn.1000-7369.2007.10.007

23. Li Y, Xi Y, Zhou C, Fang L, Liu A. Effect of compound danshen dripping pills on stable angina pectoris. *Clin J Med Off.* (2006) 34(6):673–4. doi: 10.3969/j.issn.1671-3826.2006.06.004

24. Li L, Yang H. Therapeutic effect of compound danshen dripping pills on 70 cases of stable angina pectoris. J Handan Med Coll. (2005) 18(1):34–5.

25. Huang S, Zou X, Li P. Clinical observation of compound danshen dripping pills and nitrate in the treatment of stable angina pectoris. *Mod Diagn Treat.* (2004) 15 (6):349–50. doi: 10.3969/j.issn.1001-8174.2004.06.013

26. Wang X, Shen L, Yan L. Clinical analysis of compound danshen dripping pills in treatment of stable angina pectoris. *J Inner Mongolia Med Univ.* (2003) 25(3):204–5. doi: 10.3969/j.issn.1004-2113.2003.03.023

27. Chu X, Geng J. Clinical analysis of compound danshen dripping pills in treatment of stable angina pectoris. *Heilongjiang Med J.* (2003) (4):16–7.

28. Yao X. Clinical observation of compound danshen dripping pills in treating 50 cases of angina pectoris of coronary heart disease. *J Emerg Tradit Chin.* (2002) 11 (1):26–7. doi: 10.3969/j.issn.1004-745X.2002

29. Yao F, Zhang Y, Huang M, Liu H, Sun Y. Treatment of 50 cases of stable angina pectoris with compound danshen dripping pills. *Shandong J Tradit Chin.* (2002) 21 (3):147–9. doi: 10.3969/j.issn.0257-358X.2002.03.011

30. Deng G, He J, Li B. Treatment of stable angina pectoris with compound danshen dripping pills. *Tianjin Pharm.* (2002) 14(4):48. doi: 10.3969/j.issn.1006-5687.2002.04. 029

31. Zhu Y. Comparison of curative effect of compound danshen dripping pill combined with nitrate in treating stable angina pectoris. *West J Tradit Chin Med.* (2001) 2:52–3. doi: 10.3969/j.issn.1004-6852.2001.02.046

32. Yang S, Huang T, Wang H. Effect of compound danshen dripping pills and nitrate on angina pectoris. J Wannan Med Coll. (2001) 20(3):198. doi: 10.3969/j. issn.1002-0217.2001.03.023

33. Xue F, Liu S. Clinical observation of compound danshen dripping pills in the treatment of stable angina pectoris. *J Hunan Univ Chin Med.* (2001) 21(2):36–8. doi: 10.3969/j.issn.1674-070X.2001.02.016

34. Tan S, Liu C. Clinical observation of compound danshen dripping pills in the treatment of stable angina pectoris. *Heilongjiang Med J.* (2001) 14(2):125. doi: 10. 3969/j.issn.1006-2882.2001.02

35. Shi Y, Zhang Z, Li R, Guan Y. Analysis of curative effect of compound danshen dripping pills on stable angina pectoris. *Inner Mongolia J Tradit Chin.* (2001) 05:6. doi: 10.16040/j.cnki.cn15-1101.2001.05.008

36. Lu J, Sheng H. Treatment of stable angina pectoris with compound danshen dripping pills. *West J Tradit Chin Med.* (2001) 14(6):22–3. doi: 10.3969/j.issn.1004-6852.2001.06.016

37. Guo L, Li S, Zhang W. Clinical observation of curative effect of compound danshen dripping pills on angina pectoris. *J Shandong Med Coll.* (2001) 23 (2):113–5. doi: 10.3969/j.issn.1674-0947.2001.02.011

38. Dong X, Zhang S. Effect of compound danshen dripping pills on stable angina pectoris. J Clin Med Pract. (2001) 2(3):143–5.

39. Gao B, Wu Y. Curative effect of compound danshen dripping pills on 60 cases of stable angina pectoris. J Binzhou Med Univ. (2000) 23(1):68.

40. Zhang G, Cao Y LUX, Liu Z, Liu W, Li W. Treatment of 69 cases of stable angina pectoris of coronary heart disease with compound danshen dripping pills. *Jilin J Chin Med.* (1999) 03:12.

41. Ding X, Jia L, Wang C. Comparison of the efficacy of compound danshen dripping pills in the treatment of stable angina pectoris. *Suzhou Univ J Med Sci.* (1999) 19(5):512–3.

42. Zhou Y. Treatment of 120 cases of stable angina pectoris with compound danshen dripping pills. Chin J New Drugs Clin Rem. (1998) 17(6):56–7.

43. Liu Z, Gao S, Deng J, Li H. Effect of compound danshen dropping pills on angina pectoris of coronary heart disease. *Chin Tradit Pat Med.* (1997) 19(07):20-1+53.

44. Klemenska E, Beręsewicz A. Bioactivation of organic nitrates and the mechanism of nitrate tolerance. *Cardiol J.* (2009) 16(1):11–9.

45. Hink U, Oelze M, Kolb P, Bachschmid M, Zou M-H, Daiber A, et al. Role for peroxynitrite in the inhibition of prostacyclin synthase in nitrate tolerance. J Am Coll Cardiol. (2003) 42(10):1826–34. doi: 10.1016/j.jacc.2003.07.009

46. Kosmicki MA. Long-term use of short- and long-acting nitrates in stable angina pectoris. *Curr Clin Pharmacol.* (2009) 4(2):132–41. doi: 10.2174/157488409788185016

47. Facchini E, Degiovanni A, Cavallino C, Lupi A, Rognoni A, Bongo AS. Beta-Blockers and nitrates pharmacotherapy and indications. *Cardiovasc Hematol Agents Med Chem.* (2015) 13(1):25–30. doi: 10.2174/1871525713666141219114708

48. Giuseppe C, Paul J, Hans-Ulrich I. Use of nitrates in ischemic heart. Expert Opin Pharmacother. (2015) 16(11):1567-72. doi: 10.1517/14656566.2015.1052742

49. Parker J. Potential problems with intermittent nitrate therapy. *Can J Cardiol.* (1996) 12(Suppl C):22C-4C. PMID: 8634920.

50. Munzel T, Daiber A. Inorganic nitrite and nitrate in cardiovascular therapy: a better alternative to organic nitrates as nitric oxide donors? *Vasc Pharmacol.* (2018) 102:1–10. doi: 10.1016/j.vph.2017.11.003

51. Liang J, Zhang P, Yang H, Zhang Y, Yao T, Liu K, et al. Design, synthesis and biological evaluation of novel nitric oxide donors with antioxidative activity. *Eur J Med Chem.* (2022) 236:114331. doi: 10.1016/j.ejmech.2022.114331

52. Thadani U, Rodgers T. Side effects of using nitrates to treat angina. *Expert Opin Drug Saf.* (2006) 5(5):667–74. doi: 10.1517/14740338.5.5.667

53. Yao Y, Feng Y, Lin W. Systematic review and meta-analysis of randomized controlled trials comparing compound danshen dripping pills and isosorbide dinitrate in treating angina pectoris. *Int J Cardiol.* (2015) 182:46–7. doi: 10.1016/j. ijcard.2014.12.112

54. Zheng Y, Wang X, Wang X. Pharmacoeconomic evaluation of compound danshen dripping pills and isosorbide dinitrate tablets in the treatment of stable angina pectoris based on meta—analysis. *China Pharm.* (2021) 30(12):87–91.